- |||||||||| ibentatug (ZB131) / ZielBio
Plectin as a novel therapeutic target for pancreatic cancer (Section 22; Poster Board No: 1) - Mar 25, 2025 - Abstract #AACR2025AACR_9076;
P1/2
Recently, a phase 1 clinical trial using an anti-CSP antibody, ZB131 (NCT05074472) in CSP positive cancer subtypes showed ZB131 as a viable and safe drug candidate for treatment...Additionally, treatment with anti-CSP antibody led to a decrease in classic signaling cascades associated with cancer progression such as SRC, PRAS40, STAT3, AKT, and ERK1/2. The cumulative work from this research highlights the role of CSP in PDAC and suggests a desperate need for an anti-CSP therapeutic for patients.
- |||||||||| ibentatug (ZB131) / ZielBio
Trial completion, Trial completion date, Trial primary completion date: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors (clinicaltrials.gov) - Jan 28, 2024
P1/2, N=35, Completed,
The cumulative work from this research highlights the role of CSP in PDAC and suggests a desperate need for an anti-CSP therapeutic for patients. Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2023 | Trial primary completion date: Jan 2024 --> Aug 2023
- |||||||||| ibentatug (ZB131) / ZielBio
Enrollment closed: A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors (clinicaltrials.gov) - Aug 9, 2023
P1/2, N=37, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Sep 2023 | Trial primary completion date: Jan 2024 --> Aug 2023 Recruiting --> Active, not recruiting
- |||||||||| ibentatug (ZB131) / ZielBio
ZB131 antibody-drug conjugates induce potent antitumor activity (Section 21; Poster Board #6) - Mar 14, 2023 - Abstract #AACR2023AACR_8300;
P1, P1/2
Furthermore, anti-huIgG staining revealed selective target engagement by ZB131-ADC. Taken together, these data show that ZB131-ADCs demonstrate potent antitumor activity and support their evaluation in a Phase 1 clinical trial.
- |||||||||| ZB131 / ZielBio
First in class drug ZB131 shows efficacy in cholangiocarcinoma models (La Nouvelle Orleans C, Convention Center) - Mar 9, 2022 - Abstract #AACR2022AACR_2009;
In summary, ZB131 is an exciting new avenue for the treatment of CCA and other CSP-positive cancers with an excellent safety profile and strong antitumor activity in vitro and in murine models. Phase I clinical trials of ZB131 have been initiated.
|
